AgomAb Therapeutics (NASDAQ:AGMB) Upgraded by Piper Sandler to “Strong-Buy” Rating

AgomAb Therapeutics (NASDAQ:AGMB) was upgraded by analysts at Piper Sandler to a “strong-buy” rating in a research report issued to clients and investors on Tuesday, MarketBeat Ratings reports. The firm currently has a $60.00 target price on the stock. Piper Sandler’s price target indicates a potential upside of 327.96% from the stock’s current price.

A number of other analysts have also issued reports on the stock. HC Wainwright started coverage on shares of AgomAb Therapeutics in a research note on Monday, June 22nd. They issued a “buy” rating and a $35.00 price target for the company. Wall Street Zen cut shares of AgomAb Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. B. Riley Financial initiated coverage on AgomAb Therapeutics in a report on Thursday, July 23rd. They issued a “buy” rating and a $34.00 price objective for the company. Finally, Cantor Fitzgerald started coverage on AgomAb Therapeutics in a research note on Wednesday, August 19th. They set an “overweight” rating on the stock. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $37.50.

AgomAb Therapeutics Price Performance

NASDAQ AGMB opened at $14.02 on Tuesday. The business has a 50 day moving average of $13.02. AgomAb Therapeutics has a fifty-two week low of $8.75 and a fifty-two week high of $17.82.

AgomAb Therapeutics (NASDAQ:AGMB) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.46) EPS for the quarter. As a group, sell-side analysts forecast that AgomAb Therapeutics will post -1.71 earnings per share for the current fiscal year.

About AgomAb Therapeutics

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.